Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The RNA therapeutics market was valued at USD 13.70 Billion in 2023, driven by the increasing FDA approvals for RNAi-based therapies across the globe. The market is anticipated to grow at a CAGR of 5.60% during the forecast period of 2024-2032, with the values likely to reach USD 22.37 Billion by 2032.
Base Year
Historical Year
Forecast Year
RNA therapeutics involve using RNA molecules to treat diseases by targeting gene expression at the RNA level. Key approaches include mRNA therapies, which instruct cells to produce therapeutic proteins, RNA interference (RNAi) to silence harmful genes, and antisense oligonucleotides (ASOs) to modify RNA splicing or stability. These therapies have significant potential for treating genetic disorders, cancers, and viral infections. By directly targeting the root causes of diseases at a molecular level, RNA therapeutics offer a promising and innovative approach to medicine.
Surge in FDA Approvals to Boost Market Value
The increasing prevalence of cancer and advancements in RNA-targeting technologies are significant drivers of market growth. In July 2024, Rgenta Therapeutics received FDA clearance for its Investigational New Drug (IND) application for RGT-61159, an innovative oral small molecule targeting RNA regulation. The drug is designed for the treatment of adenoid cystic carcinoma, colorectal cancer, solid tumors, and acute myeloid leukemia. This milestone highlights the shift toward RNA-based therapies in oncology. The approval is poised to accelerate investments in RNA-targeting drugs and expand the pipeline of RNA-based oncology treatments, boosting market value in the forecast period.
Rising Preference for Precision Medicine to Boost RNA Therapeutics Market Demand
Rising demand for precision medicine and breakthroughs in RNA-editing technologies drive market expansion. In November 2024, HuidaGene Therapeutics achieved FDA clearance for HG202, the first-ever CRISPR/Cas13 RNA-editing therapy designed for clinical use. This innovative treatment targets neovascular age-related macular degeneration, a leading cause of blindness. The development of HG202 underscores the growing potential of RNA-editing platforms. This approval is expected to foster competition, encourage global collaborations, and solidify RNA-editing’s role in addressing unmet medical needs, further enhancing the market’s growth trajectory during the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Type
Market Breakup by Indication
Market Breakup by End User
Market Breakup by Region
Market Segmentation by Type to Witness Growth
The market share by type constitutes mRNA therapeutics, RNA interference (RNAi) therapeutics, antisense oligonucleotide (ASO) therapeutics and others. The mRNA therapeutics segment dominates the RNA therapeutics market by type, driven by the success of mRNA-based vaccines like those for COVID-19. Its rapid adaptability to emerging diseases and scalability in production gives it an edge.
North America leads the market share due to its advanced healthcare infrastructure, strong presence of biotechnology companies, and significant investments in R&D. The region benefits from a high prevalence of target diseases, robust regulatory frameworks, and government funding supporting RNA-based drug development. Additionally, North America hosts leading players pioneering RNA technology, including mRNA vaccines and gene silencing therapies, driving rapid market growth. The early adoption of innovative therapies and strategic partnerships between academia and industry further strengthen its dominance. This competitive edge positions North America as the key driver of the market globally.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Cambridge, Massachusetts, USA, Moderna was founded in 2010. The company is a pioneer in messenger RNA (mRNA) technology, having gained global recognition for its COVID-19 vaccine, Spikevax. Moderna is also advancing mRNA-based therapeutics across multiple disease areas, including oncology, rare genetic disorders, and infectious diseases. Its expanding portfolio focuses on developing mRNA medicines that deliver genetic instructions to cells, offering potential treatments for previously hard-to-address conditions.
BioNTech, based in Mainz, Germany, was established in 2008. The company is a leader in the development of mRNA...
Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is a leader in RNA inte...
Ionis Pharmaceuticals, established in 1989 and headquartered in Carlsbad, California, specialises in antisense...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Arcturus Therapeutics Holdings Inc., CureVac N.V., Sarepta Therapeutics, Inc., Wave Life Sciences Ltd., Sanofi S.A., and Novo Nordisk A/S.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product |
|
Breakup by Type |
|
Breakup by Indication |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share